Oliver Old1, Paul Moayyedi2, Sharon Love3, Corran Roberts3, Julie Hapeshi1, Chris Foy1, Clive Stokes1, Andrew Briggs4, Janusz Jankowski5, Hugh Barr6. 1. Gloucestershire Royal Hospital, Great Western Road, Gloucester, GL1 3NN. 2. Division of Gastroenterology, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5. 3. Centre for Statistics in Medicine, University of Oxford, Botnar Research Centre, Windmill Road, Oxford, OX3 7LD. 4. University of Glasgow, Health Economics and Health Technology Assessment, Institute of Health & Wellbeing, 1 Lilybank Gardens, Glasgow G12 8RZ. 5. University Hospitals Coventry and Warwickshire, University of Warwick, Warwickshire, CV2 2DX. 6. Gloucestershire Royal Hospital, Great Western Road, Gloucester, GL1 3NN hugh.barr@glos.nhs.uk.
Abstract
OBJECTIVES: The absolute annual risk of patients with Barrett's oesophagus (BO) developing oesophageal adenocarcinoma (OAC) is ≤ 0.5%. Screening BO patients for malignant progression using endoscopic surveillance is widely practised. To assess the efficacy and cost-effectiveness of this, we developed a protocol for a randomized controlled trial of surveillance versus 'at need' endoscopy. METHODS: In a multicentre trial, 3400 BO patients randomized to either2-yearly endoscopic surveillance or 'at need' endoscopy will be followed up for 10 years. Urgent endoscopy will be offered to all patients who develop symptoms of dysphagia, unexplained weight loss > 7lb (3.2 kg), iron deficiency anaemia, recurrent vomiting, or worsening upper gastrointestinal symptoms. Participants must have endoscopically and histologically confirmed BO, with circumferential BO ≥ 1 cm or maximal tongue/island length ≥ 2 cm. Candidates with existing oesophageal high-grade dysplasia or cancer, or previous upper gastrointestinal cancer will be excluded. Primary outcome will be overall survival. Secondary outcomes will be cost effectiveness (cost per life year saved and quality adjusted life years); cancer-specific survival; time to OAC diagnosis and stage at diagnosis; morbidity and mortality related to any interventions; and frequency of endoscopy. CONCLUSIONS: This randomized trial will provide data to evaluate the efficacy and cost-effectiveness of screening BO patients for OAC.
RCT Entities:
OBJECTIVES: The absolute annual risk of patients with Barrett's oesophagus (BO) developing oesophageal adenocarcinoma (OAC) is ≤ 0.5%. Screening BO patients for malignant progression using endoscopic surveillance is widely practised. To assess the efficacy and cost-effectiveness of this, we developed a protocol for a randomized controlled trial of surveillance versus 'at need' endoscopy. METHODS: In a multicentre trial, 3400 BO patients randomized to either 2-yearly endoscopic surveillance or 'at need' endoscopy will be followed up for 10 years. Urgent endoscopy will be offered to all patients who develop symptoms of dysphagia, unexplained weight loss > 7lb (3.2 kg), iron deficiency anaemia, recurrent vomiting, or worsening upper gastrointestinal symptoms. Participants must have endoscopically and histologically confirmed BO, with circumferential BO ≥ 1 cm or maximal tongue/island length ≥ 2 cm. Candidates with existing oesophageal high-grade dysplasia or cancer, or previous upper gastrointestinal cancer will be excluded. Primary outcome will be overall survival. Secondary outcomes will be cost effectiveness (cost per life year saved and quality adjusted life years); cancer-specific survival; time to OAC diagnosis and stage at diagnosis; morbidity and mortality related to any interventions; and frequency of endoscopy. CONCLUSIONS: This randomized trial will provide data to evaluate the efficacy and cost-effectiveness of screening BO patients for OAC.
Authors: Michael S J Wilson; P Vaughan-Shaw; C Boyle; G L Yong; S Oglesby; R Skipworth; P Lamb; E A T Griffiths; S E A Attwood Journal: World J Surg Date: 2020-04 Impact factor: 3.352
Authors: James Britton; Kelly Chatten; Tom Riley; Richard R Keld; Shaheen Hamdy; John McLaughlin; Yeng Ang Journal: Frontline Gastroenterol Date: 2018-09-05
Authors: Linda C Cummings; Tzuyung Doug Kou; Amitabh Chak; Mark D Schluchter; Seunghee Margevicius; Gregory S Cooper Journal: Dig Dis Sci Date: 2021-04-21 Impact factor: 3.199